All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the EHA2021 Virtual Congress, the GvHD Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, What were the key communications on GvHD at EHA 2021?
Key communications on GvHD at EHA 2021
In this video, Mohty highlights two key presentations from EHA 2021. The first one being the phase III INTEGRATE trial of ibrutinib combined with corticosteroids in previously untreated patients with chronic GvHD. While the second communication was a subgroup analysis of the REACH2 trial evaluating the efficacy and safety of ruxolitinib in patients with steroid-refractory acute GvHD who crossed over from the best alternative treatment.
Expert Opinion from our Chair, Mohamad Mohty, on COVID-19 and GvHD
This transcript is provided from a call held between the GvHD/Multiple Myeloma Hub and Professor (Prof.) Mohamad Mohty. We would like to thank Prof. Mohty for taking the time to speak...
Practice-changing abstracts for GvHD from ASH 2019
The GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this interview, Mohamad Mohty, Saint-Antoine Hospital and...
Subscribe to get the best content related to GvHD delivered to your inbox